BioForce Nanosciences Holdings, Inc. has announced that it has closed a $6 million Private Placement of restricted common shares @$1.50/share. The company's shares trade under the symbol BFNH.
Dr. Eric Henderson, BioForce founder and CEO and an early developer of nanotechnology tools, said, "With this financing, and the recent addition of key senior management, BioForce is well positioned to take full advantage of the commercial opportunities that our NanoArrayer™ System provides."
"This funding will also facilitate continued development of the company's pipeline technologies."
BioForce's core technology, the NanoArrayer™ System, is a proprietary instrumentation and software tool that is poised to impact multiple areas in the life sciences.
The NanoArrayer™ is a platform for addressing previously intractable research problems, thereby enhancing the opportunity for scientific breakthroughs.
The company is also commercializing a patented diagnostic device called the ViriChip™ System, which is used for detection and identification of multiple viruses and other pathogens simultaneously on a single chip.